Replies to post #650286 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

And their disclosures:

And the rottenness continues.

David A Readon:

... is an advisor to Agios, AnHeart Therapeutics, Avita Biomedical, Blue Rock Therapeutics, Bristol Myers Squibb, Boston Biomedical, CureVac, Del Mar Pharma, DNAtrix, Hoffman-LaRoche, Imvax, Janssen, Kiyatec, Medicenna Therapeutics, Neuvogen, Novartis, Novocure, Pyramid, Sumitomo Dainippon Pharma, Vivacitas Oncology and Y-mabs Therapeutics.

E Antonio Chiocca

... is an advisor to Amacathera, Bionaut Labs, Genenta, Insightec, DNAtrix, Seneca Therapeutics and Theravir; he has equity options in Bionaut Laboratories, DNAtrix, Immunomic Therapeutics, Seneca Therapeutics and Ternalys Therapeutics; he is co-founder and on the board of directors of Ternalys Therapeutics

.. is a founder, board member of and holds equity in Candel Therapeutics.

“GBM has an aggressive effect in part because of a milieu of immunosuppressive factors surrounding the tumor, which enable the tumor’s growth by preventing the immune system from entering and attacking it,” said E. Antonio Chiocca, MD, PhD, chair of the BWH Department of Neurosurgery.


Patents related to oHSV and CAN-3110 are under the possession of Brigham and Women’s Hospital with E Antonio Chiocca. named as co-inventor.

https://www.genengnews.com/topics/cancer/oncolytic-virus-therapy-shows-promise-against-glioblastoma-in-first-human-trial/

[Lykiri]

Explore the groundbreaking insights from recent phase 3 trials on immunotherapy for glioblastoma, and delve into the pivotal question: is it time to embrace longitudinal sampling for better outcomes?
– by Marv

Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.

🧬🔬 Glioblastoma treatment is on the brink of a breakthrough! Phase 3 trials reveal the need for a shift in approach. Could longitudinal sampling be the key? 🗝️

Dive into the insights here:
👉 https://t.co/XGjh83OarZ#Glioblastoma #Immunotherapy #MedicalResearch #neurosurgery

— Pieter Kubben (@DigNeurosurgeon) November 24, 2023

Chen et al., Neuro Oncol 2023
DOI: 10.1093/neuonc/noad211

Oh, brace yourselves for a shocker: another set of clinical trials for glioblastoma (GBM) immunotherapy has hit the wall. Out of six phase 3 trials, a whopping five didn’t get the regulatory thumbs up. And the sixth? Well, let’s just say its fate is as uncertain as a flip of a coin. But hey, who’s counting, right?

Now, the reasons for these spectacular belly flops in the medical pool range from the tumor being a tough nut to crack, to perhaps someone not dotting their i’s and crossing their t’s in the trial designs. But fear not, for we are on a noble quest to understand the clinical and basic science behind this sextet of scientific sadness.

The rallying cry is to dive deeper into the science of human GBMs during the early trials. Apparently, the “window of opportunity” design is about as effective as a chocolate teapot for understanding the intricate dance of changes in the GBM microenvironment post-immunotherapy.

But wait, there’s a silver lining! The marriage of safer image-guided biopsies and the sexy world of “multi-omics” (sounds like a sci-fi series, doesn’t it?) allows for the longitudinal sampling of tumors and biofluids. This dynamic duo is set to unravel the Gordian knot of complex temporal changes in the GBM microenvironment in response to immunotherapy. So, grab your popcorn, because the science show is about to get real.